BIOLASE, Inc. has received regulatory clearance for Laser Bacterial Reduction (LBR) therapy indication from the FDA.
BIOLASE, Inc. has received regulatory clearance for Laser Bacterial Reduction (LBR) therapy indication from the FDA, the company announced this week.
The LBR indication now allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria, reportedly decreasing inflammation and enhancing periodontal health.
"We are extremely pleased that this new indication has been cleared by the FDA for the Epic Hygiene Laser," said BIOLASE CEO, Todd Norbe. "With this clearance, we can further expand the types of procedures hygienists can perform, directly aligning with our mission of advancing dentistry across all fields. We also believe this new indication will directly benet patients by providing a virtually-pain free and faster treatment option."
Released in December 2019, the Epic Hygiene Laser is specifically designed for dental hygienists and allows hygienists to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.
The Epic Hygiene has also received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.
For more information, visit go.biolase.com/epichygiene.
Oral Health Pavilion at HLTH 2024 Highlighted Links Between Dental and General Health
November 4th 2024At HLTH 2024, CareQuest, Colgate-Palmolive, Henry Schein, and PDS Health launched an Oral Health Pavilion to showcase how integrating oral and general health can improve patient outcomes and reduce costs.
Episode 31: Dentsply Sirona Implant Announcements
September 30th 2021DPR’s Editorial Director Noah Levine sat down with Gene Dorff, Dentsply Sirona’s group vice president of implants and Dr. Dan Butterman to review several big announcements the company made in the arena of implants during Dentsply Sirona World 2021 in Las Vegas.